Single-cell characterization of menstrual fluid at homeostasis and in endometriosis

3 Authors

- 4 Petra C. Schwalie^{1,2}, Cemsel Bafligil³, Julie Russeil¹, Magda Zachara¹, Marjan Biocanin¹,
- 5 Daniel Alpern¹, Evelin Aasna⁴, Bart Deplancke¹, Geraldine Canny⁵, Angela Goncalves^{3,4}

6 Affiliations

- ⁷ ¹Laboratory of Systems Biology and Genetics, Institute of Bioengineering, School of Life
- 8 Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne,
- 9 Switzerland.
- 10 ² Current: Roche Innovation Center Basel, Pharma Research and Early Development, Basel,
- 11 CH-4070, Switzerland
- ³ Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10
 1SA, UK.
- ⁴German Cancer Research Center (DKFZ), Somatic Evolution and Early Detection;
- 15 Heidelberg, 69120, Germany.
- ⁵ University College Dublin, Research Office, Dublin, Ireland.

17 Abstract

18 Progress in detecting and understanding endometrial conditions in women of fertile age, such

- as endometriosis, has been hampered by the invasiveness of the sample collection procedure.
 Menstrual fluid (MF) can be sampled non-invasively and could provide a unique opportunity
 to study the physiological state of tissues in the reproductive system. Despite this potential, the
 use of MF for diagnostics and research has been limited. Here we establish protocols and assess
- the feasibility of collecting and processing MF in an outpatient setting. We characterize the cellular contents of MF from 15 healthy women using flow cytometry and single-cell RNA-
- 25 sequencing, and demonstrate the ability to recover millions of live cells from the different
- cellular fractions of interest (epithelial, stromal, endothelial, perivascular and blood). Through
 computational integration of MF with endometrial samples we show that MF sampling is a
- computational integration of MF with endometrial samples we show that MF sampling is a good surrogate for endometrial biopsy. In a proof-of-principle case-control study, we collect
- 29 MF from a further 7 women with a diagnosis of endometriosis and 11 healthy controls. Through
- 30 RNA sequencing of 93 MF samples from these women we highlight important differences
- 31 between ex vivo and cultured cells, identify impaired decidualisation, low apoptosis, high
- 32 proliferation, and both higher and lower inflammatory activity in different subsets of immune
- 33 cells as distinguishing features of endometriosis patients. Finally, we identify potential novel
- 34 pan-cell-type biomarkers for this neglected condition.

35 Introduction

- 36 Menstrual fluid (MF) is an accessible source of large numbers of live cells of high biomedical
- 37 interest. During menstruation, the female body sheds 86±48ml of MF (1) containing cervico-
- 38 vaginal secretions, blood and cells from the lining of uterus, cervix, vagina, and possibly the
- 39 fallopian tube and ovaries. This rich source of live cells has been previously proposed as a NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

scalable source of live uterine NK cells (2), mesenchymal stem cells (3–7), T-cells (8) and
epithelial cells (9,10) for research and therapy.

42 Menstrual fluid has also been proposed as a sampling strategy for potential diagnosis of 43 endometriosis (11-14), a chronic, currently incurable disease that affects an estimated 10% of 44 women of reproductive age. Endometriosis occurs when cells similar to those that line the 45 inside of the uterus - the eutopic endometrium - grow outside the uterine cavity in so called 46 ectopic lesions. These ectopic, endometrial-like cells can be found on the ovaries, fallopian 47 tubes, and the tissue lining the pelvis. In rare cases, they may spread beyond the pelvic region. 48 Like the endometrial cells in the uterus, these cells outside the uterus respond to the menstrual 49 cycle. This can cause severe menstrual pain, chronic lower abdominal and pelvic pain, painful 50 intercourse, and fertility issues. The exact cause of endometriosis is not well understood and 51 its diagnosis is often delayed, taking on average 8-10 years from the onset of symptoms. This 52 delay is partly due to the necessity of laparoscopic surgery for definitive diagnosis. Progress in 53 understanding the molecular basis of endometriosis has also been hampered by the 54 invasiveness of the sample collection procedure, as well as the lack of appropriate animal 55 models. Therefore, there is a real need for non-invasive, early diagnosis methods, as well as a 56 better understanding of the disease.

57 Despite its potential for research and diagnostics, quantitative parameters of MF cellular composition, including cell-count, cell-viability, cell-type representation and transcriptional 58 59 similarity to endometrium remain only partially described (13,15–17). Moreover, it is unclear 60 whether endometriosis biomarkers identified in other tissue compartments are likewise 61 detectable in MF. To date, the identification of biomarkers for endometriosis has proven 62 challenging due to contradictory results that depend on the exact tissues being contrasted (e.g. 63 peritoneal fluid versus endometriotic lesion versus endometrial biopsy), on the phase of the 64 menstrual cycle at which the tissues were collected, or on the cell-type analysed (see (18) for a 65 systematic review of these issues).

66 MF can be acceptably and conveniently self-collected by study participants using menstrual 67 cups (19). Here, we profiled self-collected MF in a research setting at single-cell resolution to 68 ask whether MF contains a faithful representation of the cell-type composition and cellular 69 transcriptional states of the endometrium. We then compared the proportion of cell-types and

- 70 transcriptomes of the different cellular fractions of MF between endometriosis patients and
- 71 healthy controls.

72 **Results**

73 Menstrual fluid collection is a viable sampling alternative to endometrial biopsy

To quantify the cellular and molecular composition of MF, we analyzed 25 self-collected fresh MF samples from 15 healthy women on day 2 of the menstrual cycle (Sup. Table 1). MF

75 samples non 15 heating women on day 2 of the mensitual cycle (Sup. Table 1). Wi rate 76 samples were serially passed through 100 μ m and 70 μ m cell strainers and split into a flow-

77 through and a clump fraction. The retained cellular clumps were gently dissociated prior to

- 78 further processing. Flow cytometry was performed on each sample fraction staining for CD45+
- 79 (immune cells), CD45- EPCAM+ (epithelial) and CD45- EPCAM- (stromal) cell populations
- 80 (Fig. 1A).
- 81

82 *Volume, cell-viability and cell-type composition by fluorescence-activated cell sorting (FACS)*

83 The median volume of MF per sample was 5mL (Fig. 1B), with a potential donor effect (Fig. 1C-D, one-way ANOVA p-value = 0.09), but no age association (generalized linear mixed 84 model with donor random effect p-value = 0.43). Three out of 25 MF samples did not yield any 85 86 live cells, these samples came from two individuals, both of which subsequently donated again, 87 yielding samples with enough viable cells for processing. The remaining MF samples yielded 88 a median of 2.6 million live cells per mL of flow-through (Fig. 1E). There was no statistical 89 association (Pearson and Spearman correlation coefficient not significantly different from 0 at 90 a 5% significance level) between cell viability and processing time, with the sample with the 91 highest processing time delay after cup removal (12h) containing 63% live cells. After gating 92 out dead cells, flow-through MF was mainly composed of CD45+ cells (Fig. 1F, median 83% 93 of cells).

94

95 Cell-type composition and comparison to endometrial biopsy by single-cell RNA-seq

96 To characterize and quantify the cell-types found in MF, we then generated single-cell 97 transcriptomes from 7 MF samples of 4 individuals. For each sample we mixed the 3 sorted 98 populations at a 14/22/64% ratio (Fig. 2A) to obtain a balanced representation of cell-types. 99 Using established marker genes, we identified ciliated, glandular and exhausted epithelial cells, 100 mesenchymal and decidualized stromal cells, smooth muscle/endothelial cells, and immune 101 cells in all 7 samples (Fig. 2B-D, Methods). The ratio of epithelial to stromal and immune cells

102 was similar among MF samples, with epithelial cells comprising around 50% of cells (Fig. 2D).

103

104 We then asked whether the transcriptional profiles of the MF samples correspond to the 105 transcriptional profiles of freshly isolated endometrial cells by computationally integrating our single-cell data with single-cells from 3 endometrial biopsies (20) in the late-secretory and 106 107 proliferative phases of the menstrual cycle (Fig. 2E-F). Transcriptionally, MF epithelial, 108 stromal and immune cells were more similar to their corresponding cell-types in endometrial 109 biopsies than to one another, indicating that these cells are able to retain their cellular identity 110 despite being shed (Fig. 2G). Epithelial and stromal cells exhibited the highest degree of 111 transcriptomic concordance between MF and endometrial biopsy cells, whereas the immune 112 cells were more divergent, indicating that immune cells are more sensitive to shedding or 113 experimental manipulation.

114

115 Despite the overall transcriptomic concordance, we expected expression differences between 116 MF and the endometrial biopsies to reflect differences in cycle stage. The endometrial biopsy 117 samples used came from cycle stages with high progesterone levels, which represses, among 118 others, expression of many matrix metalloproteinases (MMPs). Progesterone withdrawal at 119 menstruation triggers expression of MMPs (21), an effect mediated by cytokines including 120 tumor necrosis factor- α (TNF- α). In addition, a large number of neutrophils loaded with MMPs 121 are recruited through induction of chemokines such as interleukin 8 (CXCL8) (21). Differential 122 gene expression comparison between MF and the endometrial biopsy stromal cells revealed 123 much higher expression in MF of MMPs, members of the TNF- α signaling pathway and 124 CXCL8 (Fig. 2H, Sup. Table 2).

125

In sum, our data show that sampling self-collected MF is a viable strategy for obtaining large numbers of live epithelial, stromal and immune cells from the human endometrium in an outpatient setting without prior scheduling. MF samples capture the main cell types of the

- 129 endometrium and are transcriptionally similar to cells collected via invasive biopsy.
- 130

131 **Properties of MF from patients with endometriosis and healthy controls**

132 To assess the potential of MF to provide insight into female reproductive tract disorders, we

133 collected 36 fresh MF samples from 7 women with a confirmed diagnosis of endometriosis and

134 11 age-matched healthy volunteers (Fig. 3A, Table 1, Sup. Table 3). Samples were processed

135 by density gradient to remove red blood cells. High volume samples were split into CD45+ and

136 CD45- fractions by MACS. For a subset of samples, we used FACS to estimate proportions of

- 137 CD45+ vs. CD45- cells and the CD45- fraction was further sorted into CD105+/- cells for a
- 138 estimation of the fraction of putative mesenchymal stem cells present (22).

	Donors $(n = 18)$
Median age healthy controls (range)	31 (24 – 43)
Median age endometriosis (range)	40 (22 – 49)
Diagnosis	
No known endometriosis (controls)	11
Endometriosis stage 2	2
Endometriosis stage 3	2
Endometriosis stage 4	3
Known infertility healthy controls	0
Known infertility endometriosis	3

139

140

141 Once more, we observed a donor effect on volume (Fig. 3B, ANOVA p-value 0.054). However,

we did not observe any statistically significant differences between endometriosis and healthy
 volunteer-derived MF samples in volume, cell number, cell viability, fraction of CD45+/- cells,

144 or fraction of mesenchymal stem cells (CD45-CD105+) (Fig. 3B,C). Moreover, MF volume

145 was not statistically significantly different between endometriosis stages at this sample size

146 (Fig. 3B). The vast majority of samples could be successfully cultured over multiple passages,

147 under standard mesenchymal cell culture conditions (Methods), irrespective of whether they

148 came from cases or controls.

149 Cell-type composition of ex vivo and in vitro MF cells by RNA-seq

150 To molecularly characterize both freshly isolated (ex vivo) and cultured (in vitro) samples, as 151 well as identify putative differences between endometriosis patients, we performed 3' bulk 152 RNA-sequencing on 93 samples (Fig. 4A). A principal component analysis of gene expression 153 patterns revealed two main sample groups: samples that were processed directly after isolation 154 (ex vivo) and those that were cultured (in vitro) (Fig. 4B). An over-representation analysis of 155 genes negatively correlated with PC1 (i.e. genes with higher expression in ex vivo samples) 156 revealed these to be highly enriched for blood cell-type markers, i.e. monocytes, dendritic and 157 macrophage-specific genes (Fig. 4C, Sup. Table 4). Cultured samples were transcriptionally 158 more homogeneous than freshly isolated samples, likely due culture-induced selection for 159 CD45- cells. Indeed, we observed that the CD45+ cell fraction typically failed to attach, in line 160 with previous reports that have shown preferential attachment of menstrual stromal cells (so-161 called menstrual-derived stem cells, or colony-forming cells) upon culture (23). Nevertheless, 162 when comparing in vitro cells to CD45- ex vivo cells, we observed that the transcriptional profiles remain distinct, suggesting major transcriptional shifts induced by cell culture (Fig. 163

164 4D, Sup. Table 5). In contrast, ex vivo CD45+ samples showed higher similarity to ex vivo non-

sorted (*unsorted*) samples (Fig. 4E), in line with the observation that most MF cells are CD45+as determined by FACS.

167 To confirm the differences in cell-type composition, we used an *in silico* transcriptome 168 deconvolution method (24) and a single-cell reference dataset (13) to estimate cell-type 169 fractions from our bulk RNA-seq samples. We found that indeed *in vitro* samples are 170 preponderantly composed of stromal, smooth muscle and/or endothelial-like cells, whereas *ex* 171 *vivo* samples are preponderantly composed of myeloid cells (Fig. 4F).

172 In sum, MF collected *ex vivo* and *in vitro* display transcriptional changes consistent with 173 changes in the cell-type enriched, as well as a culture induced phenotype. *In vitro* samples only

capture a subset of the cell populations initially present in MF, preponderantly stromal-like

175 cells.

176 Donor effect on transcriptomic profiles

177 Cycle-to-cycle variability in MF transcriptomic profiles has not been previously characterised.

178 There is a concern that samples might be too variable due to unpredictability in tissue

179 breakdown and exact timing of sample collection. Leveraging on having multiple longitudinal

180 samples from the same donor (Fig. 3B), we asked if MF samples are transcriptionally stable

181 across cycles of the same donor. To do so, we looked at transcriptomic concordance among

182 CD45+ *ex vivo* samples, as these were the most homogeneous in terms of their composition $(D_{12}^{-1}, D_{22}^{-1}, D_{22}^{-1},$

183 (Fig. 4F). Samples from the same donor clustered together more often than expected by chance,

184 suggesting that donor effects can be observed over multiple cycles (Fig. 4G).

185 Identification of potential transcriptional biomarkers of endometriosis in MF

186 To identify MF gene expression markers that might distinguish endometriosis from healthy

187 controls, we used three different statistical models on various subsets of the 93 RNA-seq assays

188 performed. First, we identified endometriosis biomarkers that are detectable in stromal-like

189 CD45- cells. Second, we identified biomarkers that are detectable in immune CD45+ cells.

190 Finally, we implemented a model to identify biomarkers that are detectable irrespective of cell-

191 type enriched or whether the sample is freshly isolated or cultured.

192 Differentially expressed genes in CD45- stromal-like cells

193 In this model, we sought to identify differentially expressed genes that can be found in *in vitro*

194 CD45- samples. We found 256 genes differentially expressed at a 5% false discovery rate (Fig.

195 5A, Sup. Table 6). These included the down-regulation of stromal decidualization genes

196 (20,25–27) in endometriosis patients when compared to healthy controls, supporting findings

197 that decidualization is compromised in cultured (28,29) and freshly isolated stromal cells from

198 endometriosis patients (11,13,14). Likewise, among genes downregulated in endometriosis

patients we found an enrichment for targets of estrogen receptor alpha (ESR1), whose

200 expression has been previously found to be suppressed in endometric stromal cells (30).

Additionally, we found that inflammation related pathways (TNFa signaling and IL-2/STAT5), were down-regulated in endometriosis patients, whereas epithelial to mesenchymal transition

203 (EMT) and angiogenesis were upregulated (Sup. Table 7).

Among down-regulated genes we found multiple endometriosis previously implicated in the disease including *PENK*, *MLLT11*, *HAND2-AS1* and *PDE4B*.

206 The endogenous opioid peptide precursor proenkephalin (*PENK*) has been previously reported

to be up-regulated in whole-endometrium (31,32) of endometriosis patients when compared to

208 healthy controls. In contrast, PENK expression was found to be down-regulated in ectopic

- stroma when compared to eutopic stroma of patients (33). The discrepancy in the direction of
- regulation may have to do with the specific cell-types assayed, as well as the cycle phase at
- which endometrial samples were obtained, as *PENK* expression is modulated by the menstrual
- 212 cycle (31). Interestingly, a decrease in opioid peptides has been previously suggested to be 213 involved in the maintenance of chronic inflammation in endometricois (34)
- 213 involved in the maintenance of chronic inflammation in endometriosis (34).
- 214 Consistent with our findings, the expression of mixed-lineage leukemia translocated to 11
- 215 (MLLT11) was previously found to be reduced in the ectopic stromal cells of women with
- advanced endometriosis compared to healthy controls, and its down-regulation found to be
- associated with an increased stromal cell adhesion phenotype (35).
- 218 HAND2 Antisense RNA 1 (*HAND2-AS1*), whose expression is coordinated with *HAND2* in
- human endometrial stromal cells, was also previously found to be reduced in ectopic lesions from patients compared controls, primarily expressed by stromal cells as opposed to epithelial, and that its silencing impairs stromal cell decidualization (20,26,27).
- and that its sheheing impairs stromat cen decidualization (20,20,27).
- Finally, genetic polymorphisms in cAMP-specific 3',5'-cyclic phosphodiesterase 4B (*PDE4B*)
 were recently proposed to be implicated in the etiology of endometriosis (36).
- 224 Relatively fewer genes were found to be up-regulated in endometriosis patients when compared
- to controls. Notably, the most significant up-regulated gene was fibronectin 1 (FNI). A
- 226 genome-wide meta-analysis and a subsequent targeted study have implicated single nucleotide
- 227 polymorphisms in FN1 with moderate to severe endometriosis (37,38), and relaxed fibronectin
- is being investigated as a potential target for imaging endometriotic lesions (39). At the protein
- level, studies comparing eutopic and ectopic endometrium from patients have yielded contradictory results (39). However, fibronectin levels in plasma and peritoneal fluid have
- consistently reported elevated levels in endometriosis patients when compared to healthy
- 232 women (40,41).
- 233 Differentially expressed genes in CD45+ immune cells
- We found 792 differentially expressed genes among the CD45+ *ex vivo* samples (Fig. 5B, Sup. Table 8, the one sample with an abnormally high percentage of stromal cells in Fig. 4D was excluded). We found a trend for lower expression of immune-related genes in CD45+ MF samples originating from endometriosis patients, in particular for genes related to inflammatory pathways (TNFa signaling, Inflammatory response, IFN-gamma response, Sup. Table 9).
- 238 pathways (TNFa signaling, Inflammatory response, IFN-gamma response, Sup. Table 9).
- This was intriguing, as the production of potentially pro-inflammatory cytokines, such as IL-6, has been previously found to be up-regulated in cultured and fresh stromal cells from ectopic and eutopic endometrium from patients compared to controls (13,42). To explore the activation of inflammatory pathways in specific cell-types from endometriosis patients and controls, we used AUCell (43) to score the activity of the MsigDB "inflammatory response" pathway in
- each individual cell in the dataset from Shih et al. (13) (Methods).
- In agreement with our findings, we confirmed that the activity of the inflammatory signaling pathway was significantly downregulated in myeloid (the most abundance cell-type in CD45+
- 247 ex vivo samples) and CD4+ T cells, and in a subtype of stromal cells of endometriosis patients.
- In contrast, the pathway was upregulated in uNK cells and two subtypes of CD8+ T cells of endometriosis patients (Fig. 5C). A similar pattern emerged when looking at the expression of
- 249 endometriosis patients (Fig. 5C). A similar patiern emerged w
- 250 specific inflammatory ligand receptors (Fig. 5D).
- At the opposite end of the spectrum, we identified several genes significantly more highly expressed in endometriosis patients versus healthy controls, many of which had also previously
- shown to have increased expression in the eutopic endometrium of endometriosis patients

254 compared to healthy controls (e.g. CALD1 (44) and SEMA3A (45), which has been proposed 255 to be involved in macrophage recruitment to endometriotic lesions (46)), or increased 256 expression in the eutopic endometrium of severe compared to mild endometriosis patients 257 (TEAD2 (47)). Unlike the downregulated genes, these genes were typically not immune-cell 258 specific, but rather connected to tissue invasiveness, epithelial to mesenchymal transition or 259 myc targets (Fig. 5B). C-myc expression has been previously reported to be altered in the 260 eutopic endometrium of endometriosis patients when compared to controls which, together 261 with a reduction in cell death by apoptosis, is thought to play a role in facilitating the invasive 262 features of endometriotic endometrium (48).

Interestingly, among immune-related genes, endometriosis patients also had significantly higher expression of *CD8A* (Fig. 5B). The abundance and activation levels of CD8 T cells has been a topic of considerable interest in endometriosis research. However, results vary depending on the tissue analysed (49). Our study supports the notion that CD8+ T cells (or subsets thereof (13)) are enriched in the menstrual fluid of endometriosis patients.

268 Differentially expressed genes in all cell and sample types

In the model designed to identify biomarkers that are detectable irrespective of cell type enriched or whether the sample is freshly isolated or cultured, we identified a large number of differentially expressed genes (Fig. 5F, Sup. Table 10). Many of these genes, such as *MTRNR2L1* and *HBG2*, were not, to our knowledge, previously described as biomarkers of endometriosis.

- 274 MTRNR2L1 was detected by all 3 models as being substantially upregulated in healthy controls 275 compared to endometriosis patients (Fig. 5G). As high MTRNR2L1 expression in human 276 endometrium is highly specific to endometrial epithelial glandular cells (50), the lower 277 expression of this gene in endometriosis patients might be driven either by lower expression 278 levels in their epithelial cells, or by a proportion of epithelial cells present in their MF. 279 Interestingly, despite not having been previously linked to endometriosis, MTRNR2L1 was 280 found to be downregulated in the eutopic endometrium of adenomyosis patients compared to 281 healthy controls (51).
- *HBG2* is more highly expressed in endometriosis patients than in controls (Fig. 5H). As high expression of *HBG2* is very highly specific to macrophages and erythroid cells and lowly expressed in all cell-types of the endometrium (50), we hypothesize that the origin of this signal may be in a higher proportion of macrophage cells in endometriosis patients, or in a higher amount of ambient RNA from higher levels of cell death in the samples of endometriosis patients. Intriguingly, *HBG2* was previously found to be over-expressed in the menstrual endometrium of women with heavy menstrual bleeding when compared to controls (52).

289 **Discussion**

This study demonstrates the feasibility of using self-collected MF to obtain a comprehensive cellular and molecular snapshot of the human endometrium. Our data show that MF collection

is not only viable but also yields a substantial number of live cells, including epithelial, stromal,

and immune cells. The similarity in transcriptional profiles between MF and endometrial

biopsies and recapitulation of menstrual cycle dynamics reinforces the reliability of MF as a

- representative sample of the endometrial environment. This representativeness opens avenues
- for exploring menstrual fluid in research settings and potential clinical diagnostics.

297 Our pilot study reports on useful parameters for future large-scale studies. Our data show that 298 MF is primarily composed by CD45+ myeloid cells, which dominate the transcriptomic signal. 299 Unsorted ex vivo samples vary widely in cell-type composition with no association with disease 300 state, highlighting the importance of enriching for the target cell-type in both bulk or single-301 cell transcriptomics assays. We report differences between ex vivo and in vitro (cultured cells) 302 cells, with the former containing a large number of immune-related cells, and the latter being 303 composed mainly of stromal-like cells. This stresses the importance of probing fresh cells 304 directly or having alternative specialized culture conditions if the immune compartment is to 305 be assessed. We also report on genes whose transcription in stromal cells has been previously reported to be dysregulated in endometriosis patients, but which we found to be affected by 306 307 cell culture (e.g. MARCH4, INMT or GABRP (32,53)) or menstrual cycle stage (18) (e.g. 308 PENK).

- 309 In patients with endometriosis, our MF analysis revealed distinctive gene expression patterns.
- 310 Notably, the differential expression of genes such as FN1, PDE4B, PENK, MLLT11 and
- 311 HAND2-AS1 in stromal-like cells of endometriosis patients aligns with previous findings and
- 312 underscores their potential roles in the disease's pathogenesis. Furthermore, the dysregulation
- 313 of immune-related genes in endometriosis patients suggests an altered immune landscape in
- 314 endometriosis, possibly contributing to the disease's inflammatory component. The
- 315 identification of *MTRNR2L1* and *HBG2* as potential biomarkers that are robust to cell culture 316 and cell-type enrichment is intriguing. These findings necessitate further research to validate
- 317 and understand the roles of these biomarkers in endometriosis.
- The use of MF for diagnosing endometriosis offers a promising non-invasive alternative to current diagnostic methods, which are often invasive and delayed. Our pilot study was limited by a relatively small sample size. Further research with larger cohorts with standardized collection procedures is essential to validate our findings and establish MF-based diagnostics in clinical practice.
- 323 In conclusion, our study highlights the potential of menstrual fluid as a rich, non-invasive 324 source for studying the endometrium and diagnosing endometriosis. This work paves the way 325 for further studies to explore the full diagnostic potential of menstrual fluid and its application 326 in women's health. Combined with banking stem cells isolated from MF, MF sampling can 327 enable powerful functional studies of gynecological disease.
- 328

329 Figures

330 Figure 1



332 Figure 1: Characterization of menstrual fluid from healthy donors. (A) Sample preparation for

the FACS assays. (B) Total sample volumes in mL. (C) Frequency of the number of donations
per donor. (D) Volume in mL of MF across 2-4 donations from the same donor. (E) Million of

335 live cells per mL of flow-through. (F) Percentage of CD45+ cells in flow-through.

336

331

338 Figure 2



Figure 2: Characterisation of menstrual fluid from healthy donors using single-cell RNA-seq 340 341 (scRNA-seq). (A) Sample preparation for the scRNA-seq assays. (B) Single-cell UMAP of ciliated, glandular and exhausted epithelial cells, mesenchymal and decidualized stroma, 342 343 smooth muscle/endothelial and immune cells. (C) Marker genes used for the cell-type 344 annotation. (D) Cell-type abundances in each MF sample (c - clumps, f - flow-through). (E) 345 UMAP of the MF samples integrated with endometrial biopsies from Wang et al. (20). (F) Cell-346 type abundances in MF and biopsies. (G) Gene expression correlation between the MF and biopsies. (H) Differential gene expression between stromal cells in MF and biopsies. Gene 347 348 names are shown for the top 15 genes with largest absolute log2 fold changes and for genes 349 with -log10 adjusted p-values greater than 20. Colors indicate if genes are members of the 350 pathways indicated. The pathways chosen were significantly over-represented (FDR q-value $\leq 0,00027$) in gene set enrichment analysis. 351

352 Figure 3



Figure 3: Comparison of menstrual fluid volume, cell number and cell-type proportions between endometriosis patients and healthy controls. (A) Sample preparation procedure. (B) MF volume in controls - C, and endometriosis stages 2 to 4 (E2-E4). Points are coloured by donor. (C) Cell number, viability, fraction of CD45+ cells and fraction of CD45+CD105+ cells in endometriosis - E, and controls - C.

359

353





Figure 4: Cell-type composition of MF samples by cell-type enrichment method. (A) Sample 363 364 preparation procedure. (B) Principal component analysis of all samples using the full 365 transcriptome. Shown in parentheses on the axes is the percentage of variance explained by each of the principal components. (C) Over-representation analysis of the top 30 genes 366 positively associated with PC1 in the cell-type marker gene-sets from PanglaoDB(54). P-values 367 were calculated using Fisher's exact test and corrected for multiple testing using the Benjamini-368 369 Hochberg procedure. (D) Gene expression heatmap of the 10 most significantly differentially 370 expressed genes between CD45- ex vivo and all in vitro samples. (E) Principal component 371 analysis of ex vivo samples. (F) In silico cell-type deconvolution of the bulk RNA-seq samples 372 using MuSiC. pDC - plasmacytoid dendritic cells, uNK - uterine NK cells. (G) Spearman 373 correlation of the whole CD45+ ex vivo transcriptomes for donors that donated more than once. 374 The row-side dendrogram (identical to the column-side one) was omitted.

375

Figure 5



Figure 5: Comparison of the transcriptomes between endometriosis patients and healthy controls. (A) Gene expression heatmap of 150 genes differentially expressed genes in CD45*in vitro* samples (columns). The genes shown are either 1) members of pathways significantly enriched among differentially expressed genes, or 2) top most differentially expressed genes according to p-value and absolute log2 fold-change ("Other"). (B) Gene expression heatmap

383 of 150 genes differentially expressed genes in CD45+ ex vivo samples (columns). The genes 384 shown are either 1) members of pathways significantly enriched among differentially expressed 385 genes, or 2) top most differentially expressed genes according to p-value and absolute log2 fold 386 change ("Other"). (C) Log2 fold-change of the inflammatory signaling pathway activity 387 between endometriosis patients – E, and controls – C in the different cell-types defined in Shih. 388 et al. Horizontal bars show standard errors and asterisks indicate significance level of a t-test 389 performed for each cell-type independently. P-values were adjusted for multiple testing with 390 the method from Benjamini-Hochberg. (D) Log2 fold-change of the expression of selected 391 ligand-receptors involved in inflammatory pathways between endometriosis – E and controls 392 - C. (E) Volcano plot of the differential expression of endometriosis - E - versus healthy 393 controls – C using all available samples. Points above the horizontal blue line indicate genes 394 with multiple-testing adjusted p-values below 0.05. (F) Normalised expression levels of 395 MTRNR2L1 in endometriosis - E and control - C samples. (G) Normalised expression levels 396 of HBG2 in endometriosis - E and control - C samples.

397 Methods

398 Sample collection for the healthy donor cohort

399 The study was approved by the South West - Frenchay Research Ethics Committee (IRAS 400 project ID 221351). Fifteen healthy participants (menstruating, self-defined healthy females 401 with no other selection criteria) were recruited from employees, visitors and students at the 402 Wellcome Trust Sanger Institute. All samples and data collected were solely identified by a 403 randomly assigned identifier and the research team had no access to the participant names. No 404 links were kept between A) the consent forms containing the participant name and B) the 405 samples and sample associated data collected. Participants were between 24 and 47 years old 406 with self-reported regular menstrual cycles. Two of the 15 participants were users of combined oral contraceptive pills, and a third one of a contraceptive implant. All women were requested 407 408 to collect their complete menstrual fluid during day 2 of their period using a silicone menstrual 409 cup (Mooncup®). These cups were purchased by the investigation team for the purpose of this 410 investigation. We do not hold any commercial link with this provider. Size A was 411 recommended if the person was aged 30 and over and/or has given birth vaginally at any age. 412 Size B was recommended if the person was under 30 and had not given birth vaginally. 413 Participants were asked to pour and/or pipette the sample from the Mooncup into a sample 414 collection tube and to deliver the sample tube to the study collection boxes within 6 hours of 415 menstrual cup removal. Donors were able to donate samples up to 6 times each and at each donation filled in a questionnaire with demographic and biologic data (age, time of cup 416 417 removal, current use of contraception, medication and ongoing illness). All sample collection 418 tubes and questionnaires within a kit were labeled with the same randomly assigned identifier, 419 thereby completely anonymising the samples but allowing multiple donations from the same 420 participant to be linked. Sample delivery was unscheduled and samples were processed upon 421 receipt from the collection boxes (within 30m to 12h from the time of menstrual cup removal, 422 of this time up to 3h at RT and the remainder in the fridge at 5°C).

423 Sample processing for the healthy donor cohort

424 The total volume, appearance (color, haemolysis and viscosity scores) and presence of 425 clumps/mucus were assessed for each sample. Five of the samples had high mucous content 426 and were centrifuged at 300g for 5 minutes. The supernatant was transferred to a new tube, 427 spun at 2000g for 3 minutes and resuspended with 50mL PBS. All samples were then serially 428 filtered with 100µm and 70µm nylon mesh sieves (Falcon). Clumps were backwashed from the 429 sieves with PBS and digested with collagenase for 20–60 minutes at 37°C. Flowthrough and 430 clumps were briefly centrifuged and subject to red blood cell lysis (Biolegend Inc.). Cells were 431 counted with Trypan blue. Samples with more than 1 million live cells were processed by flow 432 cytometry.

433 Flow cytometry staining and acquisition for the healthy donor cohort

434 After digestion, cells were washed and centrifuged at 2000rpm for 3 minutes. Cells were

435 resuspended in PBS plus Human TruStain FcX Blocking solution (BioLegend) and incubated

436 for 5 minutes at room temperature in the dark. 5μ /million cells of CD45 (clone 2D1,

BioLegend) and EPCAM (clone 3C4, BioLegend) antibodies were added and incubated for 1h

438 at 4°C in the dark. Post staining, cells were washed and centrifuged at 2000rpm for 3 minutes.

439 1µl/mL of DAPI was added and incubated for 5 minutes at RT. Cells were washed twice,
 440 filtered with a 50µm FACS filter and analyzed using SH800S, MoFlo XDP or BD Influx cell

441 sorters, depending on instrument availability, according to manufacturer's instructions and

442 gating strategies. After sorting, the CD45+, CD45- EPCAM- and EPCAM+ fractions were

443 collected for 10x single-cell RNA-sequencing.

444 Generation of single cell transcriptomes

445 Single-cell suspensions were loaded per channel of ChromiumTM Single Cell Chips (10X

446 Genomics® Chromium Single Cell 3' Reagent Kits v2.0), aiming for a recovery of 4,600 cells.

447 Reverse transcription and library construction were carried out according to the manufacturer's

448 recommendations. Libraries were sequenced on an Illumina HiSeq 4000 using paired-end runs

449 of 150bp.

450 Computational analysis of the single-cell RNA-seq data

Raw sequencing reads were processed using the Cell Ranger analysis pipeline (55). The 451 452 "cellranger count" command was used to generate filtered and raw matrices. Reads were 453 aligned against the human genome version GRCh38. Raw gene barcode count matrices were 454 processed using CellBender for unsupervised denoising (56) and further analyzed using the R 455 package Seurat (57). To remove low quality cells, an adaptive filtering threshold approach was 456 used based on extreme numbers of counts (count depth) and extreme numbers of genes per 457 barcode. Cells were filtered when counts or genes per barcode were less than 99% of all cells, 458 or when the mitochondrial content was higher than 10%.

To annotate cell types, we used two strategies: annotation of individually processed samples,
and annotation of all samples integrated together. For the individually processed samples,
counts were normalized using the SCT normalization approach of Seurat. Sample-specific

462 UMAPs were constructed using a subset of genes exhibiting high cell-to-cell variation which 463 were identified by modeling the mean-variance relationship. The top 3000 features were used 464 to perform PCA analysis. To cluster the cells, a K-nearest neighbor (kNN) graph based on the 465 euclidean distance in PCA space was first constructed using the first 30 PC components as 466 input. Next, the Louvain algorithm was applied to iteratively group cells. We identified the cell 467 types in each cluster using a combination of manual and automated approaches using known marker genes (Fig. 1E). First, clusters were assigned to known cell populations using cell type-468 469 specific markers obtained through the FindAllMarkers function. Multiple testing correction 470 was performed using Benjamini-Hochberg procedure. Second, the R package Garnett (58) in 471 cluster extension mode was used to annotate cells in a semi-automated manner. Integration of 472 samples was performed using reference-based canonical correlation analysis together with SCT 473 normalization (Seurat), and marker based annotation was performed as above. A consensus of 474 the three annotation strategies was used to annotate each sample.

475 Integration of the MF samples with the endometrial biopsies was performed using reference476 based canonical correlation analysis together with SCT normalization (Seurat) using 3000
477 integration features.

Differential expression analysis of menstrual fluid versus the endometrial biopsies was
 performed by generating pseudo-bulks for each of the main cell-types: stromal, epithelial and
 immune. Pseudo-bulking was performed by summing up the counts of all cells of each cell-

481 type by sample. Only genes that had non-zero counts in at least one MF and one biopsy sample

482 were kept. Samples were then used as replicates in a DESeq2 analysis using default parameters.

- 483 Log fold change shrinkage using the lfcShrink function with apeglm was performed on the
- 484 results.

485 Gene set enrichment analyses were performed using the GSEA tool (v4.3.3, (59)). Sorted

486 differentially expressed genes by log fold change were used as input to a weighted analysis487 using the following gene-sets: Hallmarks, GO Biological Process, Reactome and KEGG.

488 Sample collection and processing for the endometriosis cohort

489 We recruited age-matched (20-45) healthy female volunteers and endometriosis patients 490 through advertising at endometriosis support groups as well as the EPFL campus. The study received ethical approval by the Swiss Cantonal Authorities Vaud, CER-VD, project nr. 2016-491 492 00770. All samples and data collected were solely identified by a randomly assigned identifier. 493 Samples were processed within 6h by a standard density gradient-based cell isolation protocol 494 (Histopaque). The viability and the number of nucleated cells in the cell suspension was 495 determined using a Nucleostainer and when possible, further processed by MACS into a 496 CD45+ and CD45- fraction. For a subset of samples, surface marker gene expression was 497 determined by FACS. The isolated single cell suspension was diluted to 1×10^7 cells/ml with 498 FACS buffer (DPBS -/-) with 1% human platelet serum and the following fluorophore-499 conjugated antibodies were added: anti-human CD45 for identifying hematopoietic cells, and 500 anti-human CD105 for identifying mesenchymal stromal cells. 7-Aminoactinomycin D (7-501 AAD) was used for assessing viability and Syto40 was used for discerning nucleated cells. Cell 502 culture was performed using high glucose MEMalpha medium supplemented with 5% platelet 503 serum and 50 ug/ml Primocin. TrypLE Select reagent was used to collect the cells from the cell 504 culture plates.

505 Generation of bulk RNA-seq for the endometriosis cohort

506 RNA was collected from fresh or cultured samples into Tri-Reagent and bulk RNA-seq was 507 performed as previously described, using BRB-seq, a highly multiplexed 3' end protocol (60).

508 Computational analysis of the RNA-seq for the endometriosis cohort

509 Sequencing results were processed in the Deplancke laboratory by a standard in-house pipeline, 510 consistent with published methodology to obtain digital gene expression values for each cell 511 and estimated expression for each sample. In brief, sequenced tags were demultiplexed (at 512 sample and library level) and fastq files containing 62-bp-long single-end sequenced tags 513 (reads) were were trimmed and filtered using prinseq 0.20.3 and cutadapt 1.5 and subsequently 514 aligned to the Ensembl 84 gene annotation of the hg19 human genome using STAR 2.4.0g. 515 The number of tags per gene was calculated using htseq-count 0.6.0 with the parameters 'htseq-

- 516 count -m intersection-nonempty -s no -a 10 -t exon -i gene_id'.
- 517 The over-representation analysis in Fig. 4C was performed by taking the top 30 genes most 518 anticorrelated with PC1 from Fig. 4B and testing their enrichment in the cell-type marker gene
- 519 sets from PanglaoDB (54), using the hypergeometric test implemented in Enrichr (61).

520 The decomposition of the bulk-RNA-seq data into cell-type compositions was performed using

- 521 raw counts and cell-type annotations from the dataset in Shih et al.(13) as reference, and the
- sample deconvolution method implemented in the MuSiC R package (24), with default
- 523 parameters.

The differential gene expression analyses of endometriosis versus healthy controls were performed using the standard DESeq2 workflow (62). For the CD45- *in vitro* and CD45+ *ex vivo* cell analyses we used endometriosis (yes or no) as a fixed effect. For the "all cell and sample types" analyses we used type (*ex vivo* or *in vitro*), cell-type (unsorted, CD45+ or CD45-) and endometriosis (yes or no) as fixed effect terms.

- 529 Over representation analysis for Fig. 5A-B was performed by taking all genes significantly up 530 or down regulated in each analysis and testing for their enrichment in the MSigDB Hallmarks
- 531 gene sets (63) using the hypergeometric test implemented in Enrichr (61) and correcting for
- multiple testing. Additionally, in Fig. 5A we included differentially expressed decidualization-
- 533 associated genes. We defined decidualization-associated genes as genes whose expression
- 534 peaks in stromal cells during decidualization in Wang et al. (20) or that are known from the 535 literature.
- 536 For the scoring of the "Inflammatory signaling" pathway in the single-cells from Shih et 537 al.(13), we downloaded the gene names for this pathway from MSigDB (63) and used AUCell 538 (43) with maxrank set to 800. To test for significance of differential scoring between cell-types 539 we transformed the scores with log2(score+0.0000001) and then used a linear model with
- 540 endometriosis status (yes or no) as predictor.

541 Supplementary Materials

- 542 Sup. Table 1: Donor and sample characteristics for the healthy single-cell cohort.
- 543 Sup. Table 2: Differentially expressed genes between MF and endometrial biopsies.

- 544 Sup. Table 3: Donor and sample characteristics for the endometriosis and controls bulk-
- 545 RNA-seq cohort.
- 546 Sup. Table 4: Over-representation analysis of in vitro associated genes in the PanglaoDB cell-
- 547 type marker gene sets.
- 548 Sup. Table 5: Differentially expressed genes between in vitro and ex vivo CD45- samples.
- 549 Sup. Table 6: Differentially expressed genes between CD45- in vitro samples of
- 550 endometriosis patients versus controls.
- 551 Sup. Table 7: Over-representation analysis of the significant (padj < 0.05) genes from Sup.
- 552 Table 6.
- 553 Sup. Table 8: Differentially expressed genes between CD45+ ex vivo samples of
- 554 endometriosis patients versus controls.
- 555 Sup. Table 9: Over-representation analysis of the significant (padj < 0.05) genes from Sup.
- 556 Table 8.
- 557 Sup. Table 10: Differentially expressed genes between all samples of endometriosis patients
- 558 versus controls.

559 Author contributions

- 560 AG and PCS: designed the study.
- 561 GC: provided critical input on study design and volunteer recruitment.
- 562 CB, JR, MB, MZ and DA: collected, processed samples and performed experiments.
- 563 AG, PCS and EA: analysed data.
- 564 AG: wrote the manuscript.
- 565 BD: provided resources and input on data interpretation.
- 566 PCS: edited the manuscript.
- 567 All authors: read, commented and approved the manuscript.

568 Acknowledgements

- 569 This work was supported by an Early Detection Gynaecological Cancers Pump Priming award
- 570 by CRUK to AG. PCS was supported by an HFSP Postdoctoral Fellowship and a Diversa
- 571 Foundation Grant. We thank Suzanne Ratte for help with experimental technical assistance,
- 572 Johanne Doleman for support with the ethical application and Daniel Gaffney for support with
- 573 resources. We thank all volunteers for their participation in this study.

574 Data access

- 575 Count matrices for all sequencing data DOI: 10.5281/zenodo.11105267
- 576 ArrayExpress: accession numbers for sc and bulk RNA-seq requested, assignment pending.

577 Declaration/Conflict of interest

- The cups (LadyCup) for the endometriosis cohort were donated by Ladyplanet GmbH.
- DA, PCS and MB conducted this work while employed at EPFL in Switzerland. DA is currently employed by and holds Alithea Genomics company stock. MB is currentl employed by Lonza AG. PCS is currently employed by and holds F. Hoffmann-La Roche Ltd. company stock.

584 **References**

- Donoso MB, Serra R, Rice GE, Gana MT, Rojas C, Khoury M, et al. Normality Ranges
 of Menstrual Fluid Volume During Reproductive Life Using Direct Quantification of
 Menses with Vaginal Cups. Gynecol Obstet Invest. 2019;84(4):390–5.
- Ivarsson MA, Stiglund N, Marquardt N, Westgren M, Gidlöf S, Björkström NK.
 Composition and dynamics of the uterine NK cell KIR repertoire in menstrual blood.
 Mucosal Immunology. 2017 Mar;10(2):322–31.
- 3. Alcayaga-Miranda F, Cuenca J, Luz-Crawford P, Aguila-Díaz C, Fernandez A, Figueroa
 FE, et al. Characterization of menstrual stem cells: angiogenic effect, migration and
 hematopoietic stem cell support in comparison with bone marrow mesenchymal stem
 cells. Stem Cell Res Ther. 2015 Dec;6(1):32.
- Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, et al. Isolation, Characterization, and Transduction of Endometrial Decidual Tissue Multipotent Mesenchymal Stromal/Stem Cells from Menstrual Blood. BioMed Research International. 2013;2013:1–14.
- 599 5. Faramarzi H, Mehrabani D, Fard M, Akhavan M, Zare S, Bakhshalizadeh S, et al. The
 600 Potential of Menstrual Blood-Derived Stem Cells in Differentiation to Epidermal
 601 Lineage: A Preliminary Report. 2016;
- 602 6. Liu Y, Niu R, Yang F, Yan Y, Liang S, Sun Y, et al. Biological characteristics of human
 603 menstrual blood-derived endometrial stem cells. J Cell Mol Med. 2018 Mar;22(3):1627–
 604 39.
- 7. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG. Multipotent Menstrual
 Blood Stromal Stem Cells: Isolation, Characterization, and Differentiation. Cell
 Transplant. 2008 Mar;17(3):303–11.
- 8. Sabbaj S, Hel Z, Richter HE, Mestecky J, Goepfert PA. Menstrual Blood as a Potential
 Source of Endometrial Derived CD3+ T Cells. Landay A, editor. PLoS ONE. 2011 Dec
 9;6(12):e28894.
- 611 9. Cindrova-Davies T, Zhao X, Elder K, Jones CJP, Moffett A, Burton GJ, et al. Menstrual
 612 flow as a non-invasive source of endometrial organoids. Commun Biol. 2021 Jun
 613 17;4(1):651.
- 614 10. Filby CE, Wyatt KA, Mortlock S, Cousins FL, McKinnon B, Tyson KE, et al.
 615 Comparison of Organoids from Menstrual Fluid and Hormone-Treated Endometrium:
 616 Novel Tools for Gynecological Research. JPM. 2021 Dec 6;11(12):1314.
- 617 11. Warren LA, Shih A, Renteira SM, Seckin T, Blau B, Simpfendorfer K, et al. Analysis of
 618 menstrual effluent: diagnostic potential for endometriosis. Mol Med. 2018 Dec;24(1):1.
- 619 12. Schmitz T, Hoffmann V, Olliges E, Bobinger A, Popovici R, Nößner E, et al. Reduced
 620 frequency of perforin-positive CD8+ T cells in menstrual effluent of endometriosis
 621 patients. Journal of Reproductive Immunology. 2021 Nov;148:103424.

- 622 13. Shih AJ, Adelson RP, Vashistha H, Khalili H, Nayyar A, Puran R, et al. Single-cell
 623 analysis of menstrual endometrial tissues defines phenotypes associated with
 624 endometriosis. BMC Med. 2022 Sep 15;20(1):315.
- 625 14. Nayyar A, Saleem MI, Yilmaz M, DeFranco M, Klein G, Elmaliki KM, et al. Menstrual
 626 Effluent Provides a Novel Diagnostic Window on the Pathogenesis of Endometriosis.
 627 Front Reprod Health. 2020 Jul 22;2:3.
- 15. Van Der Molen RG, Schutten JHF, Van Cranenbroek B, Ter Meer M, Donckers J,
 Scholten RR, et al. Menstrual blood closely resembles the uterine immune microenvironment and is clearly distinct from peripheral blood. Human Reproduction. 2014
 Feb 1;29(2):303–14.
- 632 16. Fraser IS, McCarron G, Markham R, Resta T. Blood and total fluid content of menstrual
 633 discharge. Obstetrics and gynecology. 1985;65(2):194–8.
- 17. Hosseini S, Shokri F, Tokhmechy R, Savadi-Shiraz E, Jeddi-Tehrani M, Rahbari M, et al.
 Menstrual blood contains immune cells with inflammatory and anti-inflammatory
 properties. J of Obstet and Gynaecol. 2015 Nov;41(11):1803–12.
- 637 18. Brulport A, Bourdon M, Vaiman D, Drouet C, Pocate-Cheriet K, Bouzid K, et al. An
 638 integrated multi-tissue approach for endometriosis candidate biomarkers: a systematic
 639 review. Reprod Biol Endocrinol. 2024 Feb 10;22(1):21.
- 640 19. Koks CAM, Dunselman GAJ, De Goeij AFPM, Arends JW, Evers JLH. Evaluation of a
 641 menstrual cup to collect shed endometrium for in vitro studies. Fertility and Sterility.
 642 1997 Sep;68(3):560–4.
- 643 20. Wang W, Vilella F, Alama P, Moreno I, Mignardi M, Isakova A, et al. Single-cell
 644 transcriptomic atlas of the human endometrium during the menstrual cycle. Nat Med.
 645 2020 Oct;26(10):1644–53.
- 646 21. Gaide Chevronnay HP, Selvais C, Emonard H, Galant C, Marbaix E, Henriet P.
 647 Regulation of matrix metalloproteinases activity studied in human endometrium as a
 648 paradigm of cyclic tissue breakdown and regeneration. Biochimica et Biophysica Acta
 649 (BBA) Proteins and Proteomics. 2012 Jan;1824(1):146–56.
- 650 22. Mutlu L, Hufnagel D, Taylor HS. The Endometrium as a Source of Mesenchymal Stem
 651 Cells for Regenerative Medicine1. Biology of Reproduction [Internet]. 2015 Jun 1 [cited
 652 2024 Mar 6];92(6). Available from: https://academic.oup.com/biolreprod/article653 lookup/doi/10.1095/biolreprod.114.126771
- 654 23. Bozorgmehr M, Gurung S, Darzi S, Nikoo S, Kazemnejad S, Zarnani AH, et al.
 655 Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological
 656 Properties and Clinical Application. Front Cell Dev Biol. 2020 Jul 9;8:497.
- 4. Wang X, Park J, Susztak K, Zhang NR, Li M. Bulk tissue cell type deconvolution with
 multi-subject single-cell expression reference. Nat Commun. 2019 Jan 22;10(1):380.
- 659 25. Chen ST, Shi WW, Lin YQ, Yang ZS, Wang Y, Li MY, et al. Embryo-derive TNF
 660 promotes decidualization via fibroblast activation. eLife. 2023 Jul 17;12:e82970.

661	26. Liu L, Dong H, Guan Y, Fan T, Sun W, Bagchi IC, et al. Regulation of HAND2
662	Expression by LncRNA HAND2-AS1 in Ovarian Endometriosis Involving DNA
663	Methylation. Journal of the Endocrine Society. 2023 May 5;7(6):bvad049.
664	 Huyen DV, Bany BM. Evidence for a conserved function of heart and neural crest
665	derivatives expressed transcript 2 in mouse and human decidualization.
666	REPRODUCTION. 2011 Aug;142(2):353–68.
667	 Klemmt PAB, Carver JG, Kennedy SH, Koninckx PR, Mardon HJ. Stromal cells from
668	endometriotic lesions and endometrium from women with endometriosis have reduced
669	decidualization capacity. Fertility and Sterility. 2006 Mar;85(3):564–72.
670	 Barragan F, Irwin JC, Balayan S, Erikson DW, Chen JC, Houshdaran S, et al. Human
671	Endometrial Fibroblasts Derived from Mesenchymal Progenitors Inherit Progesterone
672	Resistance and Acquire an Inflammatory Phenotype in the Endometrial Niche in
673	Endometriosis1. Biology of Reproduction [Internet]. 2016 May 1 [cited 2024 Apr
674	3];94(5). Available from: https://academic.oup.com/biolreprod/article-
675	lookup/doi/10.1095/biolreprod.115.136010
676	 Bulun S, Monsavais D, Pavone M, Dyson M, Xue Q, Attar E, et al. Role of Estrogen
677	Receptor-β in Endometriosis. Semin Reprod Med. 2012 Jan;30(01):39–45.
678	 Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, et al. Gene
679	Expression Analysis of Endometrium Reveals Progesterone Resistance and Candidate
680	Susceptibility Genes in Women with Endometriosis. Endocrinology. 2007 Aug
681	1;148(8):3814–26.
682	 Chen S, Chai X, Wu X. Bioinformatical analysis of the key differentially expressed genes
683	and associations with immune cell infiltration in development of endometriosis. BMC
684	Genom Data. 2022 Mar 18;23(1):20.
685	33. Lavogina D, Samuel K, Lavrits A, Meltsov A, Sõritsa D, Kadastik Ü, et al.
686	Chemosensitivity and chemoresistance in endometriosis – differences for ectopic versus
687	eutopic cells. Reproductive BioMedicine Online. 2019 Oct;39(4):556–68.
688	34. Velho RV, Taube E, Sehouli J, Mechsner S. Neurogenic Inflammation in the Context of
689	Endometriosis—What Do We Know? IJMS. 2021 Dec 3;22(23):13102.
690 691 692 693	35. Proestling K, Husslein H, Hudson QJ, Witzmann-Stern M, Widmar B, Bagó-Horváth Z, et al. MLLT11 Regulates Endometrial Stroma Cell Adhesion, Proliferation and Survival in Ectopic Lesions of Women with Advanced Endometriosis. IJMS. 2023 Dec 28;25(1):439.
694 695 696 697	36. Yang F, Wu Y, Hockey R, Doust J, Mishra GD, Montgomery GW, et al. Evidence of shared genetic factors in the etiology of gastrointestinal disorders and endometriosis and clinical implications for disease management. Cell Reports Medicine. 2023 Nov;4(11):101250.
698	37. Sapkota Y, Steinthorsdottir V, Morris AP, Fassbender A, Rahmioglu N, De Vivo I, et al.
699	Meta-analysis identifies five novel loci associated with endometriosis highlighting key
700	genes involved in hormone metabolism. Nat Commun. 2017 May 24;8(1):15539.

- 38. Matalliotaki C, Matalliotakis M, Rahmioglu N, Mavromatidis G, Matalliotakis I,
 Koumantakis G, et al. Role of FN1 and GREB1 gene polymorphisms in endometriosis.
 Mol Med Report [Internet]. 2019 May 15 [cited 2024 Apr 3]; Available from:
 http://www.spandidos-publications.com/10.3892/mmr.2019.10247
- 705 39. Trachsel B, Imobersteg S, Valpreda G, Singer G, Grabherr R, Ormos M, et al. Relaxed
 706 fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Res.
 707 2024 Feb 10;14(1):17.
- 40. Lis-Kuberka J, Kubik P, Chrobak A, Pająk J, Chełmońska-Soyta A, Orczyk-Pawiłowicz
 M. Fibronectin Molecular Status in Plasma of Women with Endometriosis and Fertility
 Disorders. IJMS. 2021 Oct 22;22(21):11410.
- 41. Warzecha D, Załęcka J, Mańka G, Kiecka M, Lipa M, Spaczyński R, et al. Plasma and
 Peritoneal Fluid Fibronectin and Collagen IV Levels as Potential Biomarkers of
 Endometriosis. IJMS. 2022 Dec 10;23(24):15669.
- 42. Tseng JF, Ryan IP, Milam TD, Murai JT, Schriock ED, Landers DV, et al. Interleukin-6
 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from
 women with endometriosis. The Journal of Clinical Endocrinology & Metabolism. 1996
 Mar;81(3):1118–22.
- 43. Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G,
 et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods.
 2017 Nov;14(11):1083–6.
- 44. Meola J, Hidalgo GDS, Silva JCRE, Silva LECM, Paz CCP, Ferriani RA. Caldesmon:
 New Insights for Diagnosing Endometriosis1. Biology of Reproduction [Internet]. 2013
 May 1 [cited 2024 Mar 5];88(5). Available from:
- 724 https://academic.oup.com/biolreprod/article-lookup/doi/10.1095/biolreprod.112.103598
- 45. Liang Y, Wang W, Huang J, Tan H, Liu T, Shang C, et al. Potential Role of Semaphorin
 3A and Its Receptors in Regulating Aberrant Sympathetic Innervation in Peritoneal and
 Deep Infiltrating Endometriosis. Zhou R, editor. PLoS ONE. 2015 Dec
 31;10(12):e0146027.
- 46. Wu J, Xie H, Yao S, Liang Y. Macrophage and nerve interaction in endometriosis. J
 Neuroinflammation. 2017 Dec;14(1):53.
- 47. Aghajanova L, Giudice LC. Molecular Evidence for Differences in Endometrium in
 Severe Versus Mild Endometriosis. Reprod Sci. 2011 Mar;18(3):229–51.
- 48. Johnson MC, Torres M, Alves A, Bacallao K, Fuentes A, Vega M, et al. Augmented cell
 survival in eutopic endometrium from women with endometriosis: Expression of c-myc,
 TGF-beta1 and bax genes. Reprod Biol Endocrinol. 2005 Dec;3(1):45.
- 49. Kisovar A, Becker CM, Granne I, Southcombe JH. The role of CD8+ T cells in
 endometriosis: a systematic review. Front Immunol. 2023 Jul 11;14:1225639.
- 50. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al.
 Tissue-based map of the human proteome. Science. 2015 Jan 23;347(6220):1260419.

740 51. Juárez-Barber E, Corachán A, Carbajo-García MC, Faus A, Vidal C, Giles J, et al. 741 Transcriptome analysis of adenomyosis eutopic endometrium reveals molecular 742 mechanisms involved in adenomyosis-related implantation failure and pregnancy 743 disorders. Reprod Biol Endocrinol. 2024 Jan 9;22(1):10. 744 52. Girling JE, Lockhart MG, Olshansky M, Paiva P, Woodrow N, Marino JL, et al. 745 Differential Gene Expression in Menstrual Endometrium From Women With Self-746 Reported Heavy Menstrual Bleeding. Reprod Sci. 2017 Jan;24(1):28-46. 747 53. Kobayashi H, Yamashita Y, Iwase A, Yoshikawa Y, Yasui H, Kawai Y, et al. The 748 ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian 749 endometriosis. Fertility and Sterility. 2012 Aug;98(2):415-422.e12. 54. Franzén O, Gan LM, Björkegren JLM. PanglaoDB: a web server for exploration of 750 751 mouse and human single-cell RNA sequencing data. Database [Internet]. 2019 Jan 1 752 [cited 2024 Mar 6];2019. Available from: https://academic.oup.com/database/article/doi/10.1093/database/baz046/5427041 753 754 55. Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively 755 parallel digital transcriptional profiling of single cells. Nat Commun. 2017 Jan 756 16;8(1):14049. 757 56. Fleming SJ, Chaffin MD, Arduini A, Akkad AD, Banks E, Marioni JC, et al. 758 Unsupervised removal of systematic background noise from droplet-based single-cell 759 experiments using CellBender. Nat Methods [Internet]. 2023 Aug 7 [cited 2023 Aug 16]; 760 Available from: https://www.nature.com/articles/s41592-023-01943-7 761 57. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated 762 analysis of multimodal single-cell data. Cell. 2021 Jun;184(13):3573-3587.e29. 763 58. Pliner HA, Shendure J, Trapnell C. Supervised classification enables rapid annotation of cell atlases. Nat Methods. 2019 Oct;16(10):983-6. 764 765 59. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. 766 Gene set enrichment analysis: A knowledge-based approach for interpreting genome-767 wide expression profiles. Proc Natl Acad Sci USA. 2005 Oct 25;102(43):15545-50. 768 60. Alpern D, Gardeux V, Russeil J, Mangeat B, Meireles-Filho ACA, Breysse R, et al. 769 BRB-seq: ultra-affordable high-throughput transcriptomics enabled by bulk RNA 770 barcoding and sequencing. Genome Biol. 2019 Dec;20(1):71. 771 61. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive 772 and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013 773 Dec;14(1):128. 774 62. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 775 RNA-seq data with DESeq2. Genome Biol. 2014 Dec;15(12):550. 776 63. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The 777 Molecular Signatures Database Hallmark Gene Set Collection. Cell Systems. 2015 778 Dec;1(6):417-25.